A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected east africans (RV 172)

Journal of Infectious Diseases

Volumn 201, Issue 4, 2010, Pages 600-607

  Kibuuka, Hannah ^a   Kimutai, Robert ^b   Maboko, Leonard ^c   Sawe, Fred ^b   Schunk, Mirjam S ^c,d   Kroidl, Arne ^c,d   Shaffer, Douglas ^b   Eller, Leigh Anne ^a,e   Kibaya, Rukia ^b   Eller, Michael A ^a,e   Schindler, Karin B ^c,d   Schuetz, Alexandra ^c,d   Millard, Monica ^a   Kroll, Jason ^f   Dally, Len ^f   Hoelscher, Michael ^c,d   Bailer, Robert ^g   Cox, Josephine H ^h   Marovich, Mary ^e   Birx, Deborah L ⁱ   Graham, Barney S ^g   Michael, Nelson L ^e   De Souza, Mark S ^e,j   Robb, Merlin L ^e   more..

^a Makerere University   (Uganda)

^b US Army Medical Research Unit Kenya   (Kenya)

^c Mbeya Medical Research Programme   (Tanzania)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e US Military HIV Research Program   (United States)

^f EMMES CORPORATION   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^j ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; ENVELOPE PROTEIN; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; NEUTRALIZING ANTIBODY; PLACEBO; PLASMID DNA; POL PROTEIN;

ADENOVIRUS 5; ADULT; AFRICA; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW UP; GASTROENTERITIS; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALAISE; MALARIA; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VACCINATION; VIRUS REPLICATION;

ADENOVIRIDAE; ADOLESCENT; ADULT; AFRICA, EASTERN; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DNA, VIRAL; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PLASMIDS; VACCINES, DNA; YOUNG ADULT;

EID: 75749141272     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/650299     Document Type: Article

References (24)

1. UNAIDS/WHO. Report on the Global AIDS Epidemic. Geneva, Switzerland: UNAIDS, 2008.
2. Gray RH, Wawer MJ, Serwadda D, Kigozi G. The role of male circumcision in the prevention of human papillomavirus and HIV infection. J Infect Dis 2009; 199:1-3.
3. Karim SA, Coletti, A, Richardson, B, et al. Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PRO 2005/5 Gel for the prevention of HIV infection in women: results of the HPTN 035 trial [abstract 48LB]. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections, Montreal, Canada, 2009.
4. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a doubleblind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-1893.
5. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665.
6. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671. (Pubitemid 44901996)
7. Johnston MI, Fauci AS. An HIV vaccine-challenges and prospects. N Engl J Med 2008; 359:888-890.
8. Walker BD, Burton DR. Toward an AIDS vaccine. Science 2008; 320: 760-764.
9. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008; 14:617-621.
10. Nabel GJ. Mapping the future of HIV vaccines. Nat Rev Microbiol 2007; 5:482-484.
11. Letvin NL, Mascola JR, Sun Y, et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312:1530-1533. (Pubitemid 43865893)
12. Mattapallil JJ, Douek DC, Buckler-White A, et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 2006; 203:1533-1541. (Pubitemid 43877613)
13. Sun Y, Schmitz JE, Buzby AP, et al. Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol 2006; 80:10950-10956. (Pubitemid 44706536)
14. Casimiro DR, Wang F, Schleif WA, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005; 79:15547-15555. (Pubitemid 43032336)
15. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194:1638-1649. (Pubitemid 44901994)
16. Catanzaro AT, Roederer M, Koup RA, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007; 25:4085-4092. (Pubitemid 46616987)
17. Kostense S, Koudstaal W, Sprangers M, et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004; 18:1213-1216. (Pubitemid 38738525)
18. Currier JR, Kuta EG, Turk E, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002; 260:157-172. (Pubitemid 34132882)
19. Fu TM, Dubey SA, Mehrotra DV, et al. Evaluation of cellular immune responses in subjects chronically infected with HIV type 1. AIDS Res Hum Retroviruses 2007; 23:67-76.
20. Guwatudde D, Wabwire-Mangen F, Eller LA, et al. Relatively low HIV infection rates in rural Uganda, but with high potential for a rise: a cohort study in Kayunga District, Uganda. PLoS ONE 2009; 4:e4145.
21. Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006; 6:930-939. (Pubitemid 44851735)
22. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
23. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-1905.
24. Schuetz A, Haule A, Schunk M, et al. Cellular immune responses in HIV-1 uninfected adult Tanzanian volunteers enrolled in a phase I/II multiclade HIV-1 DNA plasmid vaccine (VRC-HIVDNA016-00-VP)/Adenovirus-5 Vector (VRC-HIVADV014-00-VP) boost vaccine trial [abstract 86]. In: Program and abstracts of Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 2008.